<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104161">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01862861</url>
  </required_header>
  <id_info>
    <org_study_id>Medimix Pharm-02</org_study_id>
    <nct_id>NCT01862861</nct_id>
  </id_info>
  <brief_title>Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study</brief_title>
  <acronym>REVERT</acronym>
  <official_title>Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medimix Specialty Pharmacy, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medimix Specialty Pharmacy, LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioidentical Hormone Replacement Therapy (BHRT) to assess a change in the number of various
      menopausal symptoms such as hot flashes and night sweats in surgically or naturally induced
      peri or post-menopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be receiving a customized bioidentical hormone regimen which may include a
      combination of estrogens, progesterone, and testosterone.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To evaluate the efficacy of bioidentical hormone replacement therapy in decreasing the severity of vasomotor symptoms.</measure>
    <time_frame>12 Week Study</time_frame>
    <safety_issue>No</safety_issue>
    <description>The reduction of severity of vasomotor symptoms will be evaluated by utilizing the Menopause Rating Scale (MRS) from baseline to the end of study at 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate health-related quality of life (HrQol)</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The quality of life (HrQol) will be evaluated by utilizing the Women's Health Questionnaire (WHQ)at baseline and at end of study at 12 weeks.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">69</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Peri or post-menopausal women.</arm_group_label>
    <description>Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Peri-menopausal or post-menopausal women between the age of 30 and 65 years of age.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be women who are in surgically or naturally induced menopause or
             perimenopause, as determined by their physician.

          -  Participants must be starting a new regimen of bioidentical hormone replacement
             therapy.

          -  Participants must be expected to receive therapy for at least 12 weeks.

          -  Participants must be between 30 and 65 years of age.

          -  Participants must be able to provide sound written informed consent or have an
             acceptable surrogate capable of giving consent on the subject's behalf.

        Exclusion Criteria:

          -  Participants must not have prior hypersensitivity or adverse events to any of the
             components in the customized prescription.

          -  Participants must not be pregnant or breastfeeding women.

          -  Participants must not be managed outside the Medimix Specialty Pharmacy system with
             regard to their bioidentical hormone replacement therapy.

          -  Participants must not be using another bioidentical hormone at the time of
             enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin J Epstein, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>The Medimix Specialty Pharmacy, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Medimix Specialty Pharmacy, LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Holtorf K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgrad Med. 2009 Jan;121(1):73-85. doi: 10.3810/pgm.2009.01.1949. Review.</citation>
    <PMID>19179815</PMID>
  </reference>
  <reference>
    <citation>Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006 Jul;96(7):1226-35. Epub 2006 May 30.</citation>
    <PMID>16735636</PMID>
  </reference>
  <reference>
    <citation>Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002978. Review.</citation>
    <PMID>15495039</PMID>
  </reference>
  <reference>
    <citation>Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes. 2004 Nov 22;2:67.</citation>
    <PMID>15555079</PMID>
  </reference>
  <reference>
    <citation>Julious SA, Campbell MJ. Sample size calculations for paired or matched ordinal data. Stat Med. 1998 Jul 30;17(14):1635-42.</citation>
    <PMID>9699235</PMID>
  </reference>
  <reference>
    <citation>Julious SA, Campbell MJ, Altman DG. Estimating sample sizes for continuous, binary, and ordinal outcomes in paired comparisons: practical hints. J Biopharm Stat. 1999 May;9(2):241-51.</citation>
    <PMID>10379691</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 22, 2013</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioidentical Hormone Replacement Therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
